US4604376A
(en)
*
|
1982-04-21 |
1986-08-05 |
Research Corporation |
Enteric compounds and complexes
|
US4914084A
(en)
*
|
1984-05-09 |
1990-04-03 |
Synthetic Blood Corporation |
Composition and method for introducing heme, hemoproteins, and/or heme-hemoprotein complexes into the body
|
EP0179904A1
(de)
*
|
1984-05-09 |
1986-05-07 |
Medaphore Inc. |
Orales insulin und verfahren zu seiner herstellung
|
DE3443877A1
(de)
*
|
1984-06-09 |
1985-12-12 |
Hoechst Ag |
Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung
|
CA1257199A
(en)
*
|
1986-05-20 |
1989-07-11 |
Paul Y. Wang |
Preparation containing bioactive macromolecular substance for multi-months release in vivo
|
FR2605449B1
(fr)
*
|
1986-10-17 |
1988-12-02 |
Thomson Cgr |
Bloc magnetique a aimantation ajustable pour la production d'un champ magnetique permanent dans une zone d'interet
|
NZ222907A
(en)
*
|
1986-12-16 |
1990-08-28 |
Novo Industri As |
Preparation for intranasal administration containing a phospholipid absorption enhancing system
|
US5179079A
(en)
*
|
1986-12-16 |
1993-01-12 |
Novo Nordisk A/S |
Nasal formulation and intranasal administration therewith
|
US5266310A
(en)
*
|
1987-09-17 |
1993-11-30 |
Boehringer Ingelheim International Gmbh |
Stabilization of therapeutically active proteins in pharmaceutical preparations
|
NZ228285A
(en)
*
|
1988-03-11 |
1991-08-27 |
Teikoku Seiyaku Kk |
Pharmaceutical composition comprising a polypeptide and adapted for intravaginal administration
|
US5725871A
(en)
*
|
1989-08-18 |
1998-03-10 |
Danbiosyst Uk Limited |
Drug delivery compositions comprising lysophosphoglycerolipid
|
GB9007052D0
(en)
*
|
1990-03-29 |
1990-05-30 |
Skua Investments Ltd |
Pharmaceutical formulations
|
ATE140034T1
(de)
*
|
1990-04-17 |
1996-07-15 |
Analytical Control Syst Inc |
Koagulationsassays und reagenzien
|
DE4208552A1
(de)
*
|
1992-03-17 |
1993-09-23 |
Liedtke Pharmed Gmbh |
Topische arzneiformen mit insulin
|
ES2218543T3
(es)
|
1994-03-07 |
2004-11-16 |
Nektar Therapeutics |
Procedimiento y preparacion para la administracion de insulina por via pulmonar.
|
US6214375B1
(en)
|
1996-07-16 |
2001-04-10 |
Generex Pharmaceuticals, Inc. |
Phospholipid formulations
|
DE19726167B4
(de)
|
1997-06-20 |
2008-01-24 |
Sanofi-Aventis Deutschland Gmbh |
Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
|
US6221378B1
(en)
|
1998-02-10 |
2001-04-24 |
Generex Pharmaceuticals Incorporated |
Mixed micellar delivery system and method of preparation
|
US6350458B1
(en)
|
1998-02-10 |
2002-02-26 |
Generex Pharmaceuticals Incorporated |
Mixed micellar drug deliver system and method of preparation
|
US7070799B1
(en)
*
|
1998-02-10 |
2006-07-04 |
Generex Pharmaceuticals, Inc. |
Method for administering insulin to the buccal region
|
US6017545A
(en)
*
|
1998-02-10 |
2000-01-25 |
Modi; Pankaj |
Mixed micellar delivery system and method of preparation
|
US6290987B1
(en)
|
1998-09-27 |
2001-09-18 |
Generex Pharmaceuticals, Inc. |
Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
|
US6849263B2
(en)
*
|
1998-12-21 |
2005-02-01 |
Generex Pharmaceutical Incorporated |
Pharmaceutical compositions for buccal delivery of pain relief medications
|
US6271200B1
(en)
|
1998-12-21 |
2001-08-07 |
Generex Pharmaceuticals Inc. |
Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
|
US6436367B1
(en)
|
1998-12-21 |
2002-08-20 |
Generex Pharmaceuticals Inc. |
Aerosol formulations for buccal and pulmonary application
|
US7087215B2
(en)
*
|
1998-12-21 |
2006-08-08 |
Generex Pharmaceuticals Incorporated |
Methods of administering and enhancing absorption of pharmaceutical agents
|
US6451286B1
(en)
|
1998-12-21 |
2002-09-17 |
Generex Pharmaceuticals Incorporated |
Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
|
US6375975B1
(en)
|
1998-12-21 |
2002-04-23 |
Generex Pharmaceuticals Incorporated |
Pharmaceutical compositions for buccal and pulmonary application
|
DE10114178A1
(de)
|
2001-03-23 |
2002-10-10 |
Aventis Pharma Gmbh |
Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
|
US20030068361A1
(en)
*
|
2001-10-09 |
2003-04-10 |
Rimona Margalit |
Liposome-encapsulated insulin formulations
|
WO2003094956A1
(en)
|
2002-05-07 |
2003-11-20 |
Novo Nordisk A/S |
Soluble formulations comprising monomeric insulin and acylated insulin
|
US8435942B2
(en)
*
|
2002-05-31 |
2013-05-07 |
Transdermal Biotechnology, Inc. |
Methods for formulating stabilized insulin compositions
|
US20040018237A1
(en)
*
|
2002-05-31 |
2004-01-29 |
Perricone Nicholas V. |
Topical drug delivery using phosphatidylcholine
|
DE10227232A1
(de)
*
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
US8911751B2
(en)
*
|
2005-10-11 |
2014-12-16 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Compositions for nasal delivery
|
EP2910569B1
(de)
|
2008-03-18 |
2016-10-05 |
Novo Nordisk A/S |
Proteasestabilisierte, acylierte Insulinanaloga
|
HUE037449T2
(hu)
|
2008-10-17 |
2018-08-28 |
Sanofi Aventis Deutschland |
Egy inzulin és egy GLP-1 agonista kombinációja
|
ES2965209T3
(es)
|
2009-11-13 |
2024-04-11 |
Sanofi Aventis Deutschland |
Composición farmacéutica que comprende desPro36exendina-4(1-39)-Lys6-NH2 y metionina
|
EP3831402A1
(de)
|
2009-11-13 |
2021-06-09 |
Sanofi-Aventis Deutschland GmbH |
Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten, ein insulin und methionin
|
CN104001159B
(zh)
*
|
2010-07-14 |
2016-08-24 |
中国医学科学院药物研究所 |
一种胰岛素的脂质复合物及其制备方法和制剂
|
PT2611458T
(pt)
|
2010-08-30 |
2016-12-16 |
Sanofi Aventis Deutschland |
Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
|
US8668937B2
(en)
|
2011-03-17 |
2014-03-11 |
Transdermal Biotechnology, Inc. |
Topical nitric oxide systems and methods of use thereof
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
AR087693A1
(es)
|
2011-08-29 |
2014-04-09 |
Sanofi Aventis Deutschland |
Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
|
AR087744A1
(es)
|
2011-09-01 |
2014-04-16 |
Sanofi Aventis Deutschland |
Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
|
US8871257B2
(en)
|
2012-09-19 |
2014-10-28 |
Transdermal Biotechnology, Inc. |
Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
|
US8871254B2
(en)
|
2012-09-19 |
2014-10-28 |
Transdermal Biotechnology, Inc. |
Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
|
US8871255B2
(en)
|
2012-09-19 |
2014-10-28 |
Transdermal Biotechnology, Inc. |
Treatment of skin and soft tissue infection with nitric oxide
|
US8871258B2
(en)
|
2012-09-19 |
2014-10-28 |
Transdermal Biotechnology, Inc. |
Treatment and prevention of learning and memory disorders
|
US8871260B2
(en)
|
2012-09-19 |
2014-10-28 |
Transdermal Biotechnology, Inc. |
Methods and compositions for muscular and neuromuscular diseases
|
US8871256B2
(en)
|
2012-09-19 |
2014-10-28 |
Transdermal Biotechnology, Inc. |
Methods and systems for treatment of inflammatory diseases with nitric oxide
|
US8871259B2
(en)
|
2012-09-19 |
2014-10-28 |
Transdermal Biotechnology, Inc. |
Techniques and systems for treatment of neuropathic pain and other indications
|
US8871261B2
(en)
|
2012-09-19 |
2014-10-28 |
Transdermal Biotechnology, Inc. |
Cancer treatments and compositions for use thereof
|
US8871262B2
(en)
|
2012-09-19 |
2014-10-28 |
Transdermal Biotechnology, Inc. |
Compositions and methods for treatment of osteoporosis and other indications
|
US20140271938A1
(en)
|
2013-03-13 |
2014-09-18 |
Transdermal Biotechnology, Inc. |
Systems and methods for delivery of peptides
|
US9314433B2
(en)
|
2013-03-13 |
2016-04-19 |
Transdermal Biotechnology, Inc. |
Methods and systems for treating or preventing cancer
|
US9314423B2
(en)
|
2013-03-13 |
2016-04-19 |
Transdermal Biotechnology, Inc. |
Hair treatment systems and methods using peptides and other compositions
|
US9393264B2
(en)
|
2013-03-13 |
2016-07-19 |
Transdermal Biotechnology, Inc. |
Immune modulation using peptides and other compositions
|
US9314417B2
(en)
|
2013-03-13 |
2016-04-19 |
Transdermal Biotechnology, Inc. |
Treatment of skin, including aging skin, to improve appearance
|
US9314422B2
(en)
|
2013-03-13 |
2016-04-19 |
Transdermal Biotechnology, Inc. |
Peptide systems and methods for metabolic conditions
|
US9687520B2
(en)
|
2013-03-13 |
2017-06-27 |
Transdermal Biotechnology, Inc. |
Memory or learning improvement using peptide and other compositions
|
US9387159B2
(en)
|
2013-03-13 |
2016-07-12 |
Transdermal Biotechnology, Inc. |
Treatment of skin, including aging skin, to improve appearance
|
US9295636B2
(en)
|
2013-03-13 |
2016-03-29 |
Transdermal Biotechnology, Inc. |
Wound healing using topical systems and methods
|
US9241899B2
(en)
|
2013-03-13 |
2016-01-26 |
Transdermal Biotechnology, Inc. |
Topical systems and methods for treating sexual dysfunction
|
US9750787B2
(en)
|
2013-03-13 |
2017-09-05 |
Transdermal Biotechnology, Inc. |
Memory or learning improvement using peptide and other compositions
|
US20140271937A1
(en)
|
2013-03-13 |
2014-09-18 |
Transdermal Biotechnology, Inc. |
Brain and neural treatments comprising peptides and other compositions
|
US9393265B2
(en)
|
2013-03-13 |
2016-07-19 |
Transdermal Biotechnology, Inc. |
Wound healing using topical systems and methods
|
US9320758B2
(en)
|
2013-03-13 |
2016-04-26 |
Transdermal Biotechnology, Inc. |
Brain and neural treatments comprising peptides and other compositions
|
US9339457B2
(en)
|
2013-03-13 |
2016-05-17 |
Transdermal Biotechnology, Inc. |
Cardiovascular disease treatment and prevention
|
US9295637B2
(en)
|
2013-03-13 |
2016-03-29 |
Transdermal Biotechnology, Inc. |
Compositions and methods for affecting mood states
|
US9295647B2
(en)
|
2013-03-13 |
2016-03-29 |
Transdermal Biotechnology, Inc. |
Systems and methods for delivery of peptides
|
US9320706B2
(en)
|
2013-03-13 |
2016-04-26 |
Transdermal Biotechnology, Inc. |
Immune modulation using peptides and other compositions
|
US20140271731A1
(en)
|
2013-03-13 |
2014-09-18 |
Transdermal Biotechnology, Inc. |
Cardiovascular disease treatment and prevention
|
US9724419B2
(en)
|
2013-03-13 |
2017-08-08 |
Transdermal Biotechnology, Inc. |
Peptide systems and methods for metabolic conditions
|
US9849160B2
(en)
|
2013-03-13 |
2017-12-26 |
Transdermal Biotechnology, Inc. |
Methods and systems for treating or preventing cancer
|
DK3229828T5
(da)
|
2014-12-12 |
2024-10-14 |
Sanofi Aventis Deutschland |
Formulering med fast forhold mellem insulin glargin og lixisenatid
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
JP6690062B2
(ja)
|
2016-12-16 |
2020-04-28 |
ノヴォ ノルディスク アー/エス |
インスリン含有医薬組成物
|
CA3070156A1
(en)
|
2017-07-20 |
2019-01-24 |
Yissum Research Development Company Of The Hebrew University Of Jerusam Ltd. |
Pharmaceutical film compositions for delivery of lipophilic compounds into and/or across the skin
|